168 related articles for article (PubMed ID: 37735204)
1. Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition.
Zhao M; Li L; Kiernan CH; Castro Eiro MD; Dammeijer F; van Meurs M; Brouwers-Haspels I; Wilmsen MEP; Grashof DGB; van de Werken HJG; Hendriks RW; Aerts JG; Mueller YM; Katsikis PD
Sci Rep; 2023 Sep; 13(1):15678. PubMed ID: 37735204
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK.
Li L; Zhao M; Kiernan CH; Castro Eiro MD; van Meurs M; Brouwers-Haspels I; Wilmsen MEP; Grashof DGB; van de Werken HJG; Hendriks RW; Mueller YM; Katsikis PD
Front Immunol; 2023; 14():1201415. PubMed ID: 37771591
[TBL] [Abstract][Full Text] [Related]
3. Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade.
Tian W; Qin G; Jia M; Li W; Cai W; Wang H; Zhao Y; Bao X; Wei W; Zhang Y; Shao Q
Front Immunol; 2023; 14():1198551. PubMed ID: 37398674
[TBL] [Abstract][Full Text] [Related]
4. PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells.
Viramontes KM; Neubert EN; DeRogatis JM; Tinoco R
Front Immunol; 2022; 13():869768. PubMed ID: 35774790
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
Front Immunol; 2022; 13():872295. PubMed ID: 35634282
[TBL] [Abstract][Full Text] [Related]
6. Strategies to reinvigorate exhausted CD8
Guan Q; Han M; Guo Q; Yan F; Wang M; Ning Q; Xi D
Front Immunol; 2023; 14():1204363. PubMed ID: 37398660
[TBL] [Abstract][Full Text] [Related]
7. The β
Globig AM; Zhao S; Roginsky J; Maltez VI; Guiza J; Avina-Ochoa N; Heeg M; Araujo Hoffmann F; Chaudhary O; Wang J; Senturk G; Chen D; O'Connor C; Pfaff S; Germain RN; Schalper KA; Emu B; Kaech SM
Nature; 2023 Oct; 622(7982):383-392. PubMed ID: 37731001
[TBL] [Abstract][Full Text] [Related]
8. Fundamentals to therapeutics: Epigenetic modulation of CD8
Blake MK; O'Connell P; Aldhamen YA
Front Cell Dev Biol; 2022; 10():1082195. PubMed ID: 36684449
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance.
Sridaran D; Chouhan S; Mahajan K; Renganathan A; Weimholt C; Bhagwat S; Reimers M; Kim EH; Thakur MK; Saeed MA; Pachynski RK; Seeliger MA; Miller WT; Feng FY; Mahajan NP
Nat Commun; 2022 Nov; 13(1):6929. PubMed ID: 36376335
[TBL] [Abstract][Full Text] [Related]
10. The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment.
Luo H; Wang W; Mai J; Yin R; Cai X; Li Q
Front Immunol; 2023; 14():1267918. PubMed ID: 37881432
[TBL] [Abstract][Full Text] [Related]
11. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
12. Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model.
Hope JL; Spantidea PI; Kiernan CH; Stairiker CJ; Rijsbergen LC; van Meurs M; Brouwers-Haspels I; Mueller YM; Nelson DJ; Bradley LM; Aerts JGJV; Katsikis PD
Front Immunol; 2019; 10():3074. PubMed ID: 31998326
[TBL] [Abstract][Full Text] [Related]
13. BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment.
Tseng HY; Alavi S; Gallagher S; McGuire HM; Hersey P; Al Emran A; Tiffen J
Pigment Cell Melanoma Res; 2024 May; ():. PubMed ID: 38725219
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects.
Modur V; Muhammad B; Yang JQ; Zheng Y; Komurov K; Guo F
Cell Rep; 2023 Apr; 42(4):112364. PubMed ID: 37043352
[TBL] [Abstract][Full Text] [Related]
15. Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade.
Budimir N; Thomas GD; Dolina JS; Salek-Ardakani S
Cancer Immunol Res; 2022 Feb; 10(2):146-153. PubMed ID: 34937730
[TBL] [Abstract][Full Text] [Related]
16. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
[TBL] [Abstract][Full Text] [Related]
17. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant immune checkpoint blockade triggers persistent and systemic T
Blomberg OS; Kos K; Spagnuolo L; Isaeva OI; Garner H; Wellenstein MD; Bakker N; Duits DEM; Kersten K; Klarenbeek S; Hau CS; Kaldenbach D; Raeven EAM; Vrijland K; Kok M; de Visser KE
Oncoimmunology; 2023; 12(1):2201147. PubMed ID: 37089449
[TBL] [Abstract][Full Text] [Related]
19. The Potential of T Cell Factor 1 in Sustaining CD8
Jung S; Baek JH
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33572793
[TBL] [Abstract][Full Text] [Related]
20. Hierarchy of signaling thresholds downstream of the T cell receptor and the Tec kinase ITK.
Gallagher MP; Conley JM; Vangala P; Garber M; Reboldi A; Berg LJ
Proc Natl Acad Sci U S A; 2021 Aug; 118(35):. PubMed ID: 34452995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
